ABBV-333 vs Sunakiment

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Asthma

Shared mechanism: TSLP · full Asthma pipeline

ABBV-333

Developed by AbbVie

undisclosed
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Sunakiment

Developed by AstraZeneca and partners

Phase 2 in Asthmaantibody fragment
Partial signal

NCT06529419 · Phase 2 · completed

The study randomized 537 participants across three AZD8630 dose groups and placebo, with participants, care providers, investigators, and outcome assessors quadruple-blinded. Its primary endpoint was a clinical exacerbation-related measure, but the primary comparison cannot yet be judged because results have not been reported.

Reported efficacy

Part A and Part B: Number of participants with adverse events (Until Follow-up (FU) Visit/Early Termination (ET) Visit (Part A: 7-day post-dose for SAD; 10-day post-last dose for MAD) and Part B: Until FU Visit/ET Visit (10-day post-last dose)); Part A (IV cohort): Time to reach maximum observed concentration (tmax) of AZD8630 (Pre-dose and Post-dose on Days 1 to 4 and Follow-up Visit/ET Visit (7-day post-dose)); Part A (IV cohort): Time of last observed quantifiable concentration (tlast) of AZD8630 (Pre-dose and Post-dose on Days 1 to 4 and Follow-up Visit/ET Visit (7-day post-dose)); Part A (IV cohort): Maximum observed serum (peak) drug concentration (Cmax) of AZD8630 (Pre-dose and Post-dose on Days 1 to 4 and Follow-up Visit/ET Visit (7-day post-dose)); Part A (IV cohort): Partial area under the serum concentration-time curve from 0 to time 24 hours post-dose [AUC(0-24)] of AZD8630 (Pre-dose and Post-dose on Days 1 to 4 and Follow-up Visit/ET Visit (7-day post-dose)); Part A (IV cohort): Area under the serum concentration curve from zero to the last quantifiable concentration (AUClast) of AZD8630 (Pre-dose and Post-dose on Days 1 to 4 and Follow-up Visit/ET Visit (7-day post-dose)); Part A (IV cohort): Area under serum concentration-time curve from zero to infinity (AUCinf) of AZD8630 (Pre-dose and Post-dose on Days 1 to 4 and Follow-up Visit/ET Visit (7-day post-dose)); Part A (IV cohort): Terminal rate constant (λz) of AZD8630 (Pre-dose and Post-dose on Days 1 to 4 and Follow-up Visit/ET Visit (7-day post-dose)); Part A (IV cohort): Half-life associated with terminal slope (λz) of a semi-logarithmic concentration-time curve (t1/2λz) of AZD8630 (Pre-dose and Post-dose on Days 1 to 4 and Follow-up Visit/ET Visit (7-day post-dose)); Part A (IV cohort): Mean residence time of the unchanged drug in the systemic circulation (MRTinf) of AZD8630 (Pre-dose and Post-dose on Days 1 to 4 and Follow-up Visit/ET Visit (7-day post-dose)); Part A (IV cohort): Total body clearance of drug from serum after IV administration (CL) of AZD8630 (Pre-dose and Post-dose on Days 1 to 4 and Follow-up Visit/ET Visit (7-day post-dose)); Part A (IV cohort): Volume of distribution at steady state (Vss) of AZD8630 (Pre-dose and Post-dose on Days 1 to 4 and Follow-up Visit/ET Visit (7-day post-dose)); Part A (IV Cohort): Volume of distribution of drug from serum after IV administration (Vz) of AZD8630 (Pre-dose and Post-dose on Days 1 to 4 and Follow-up Visit/ET Visit (7-day post-dose)); Part A (IV Cohort): Number of participants with adverse events (Until Follow-up (FU) Visit/Early Termination (ET) Visit (7-day post-dose)): Primary outcome, adverse events in Part A (healthy adults) and Part B (asthma): acceptable safety profile, low incidence of treatment-induced antidrug antibodies (part A n=1; part B n=2); safety outcome, no formal efficacy test. The other registered primaries are pharmacokinetic. Secondary outcome, FeNO change vs placebo at day 28 in Part B: 23% reduction with 8 mg (P=.037). (not_applicable)

Result source: NCT05110976

Results for Asthma

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointABBV-333Sunakiment
Severe exacerbations, annualised rate—Not reported—Not reported
Trough FEV1, change—Not reported—Not reported
ACQ-5, change—Not reported—Not reported
OCS dose reduction—Not reported—Not reported

Severe exacerbations, annualised rate

ABBV-333
—Not reported
Sunakiment
—Not reported

Trough FEV1, change

ABBV-333
—Not reported
Sunakiment
—Not reported

ACQ-5, change

ABBV-333
—Not reported
Sunakiment
—Not reported

OCS dose reduction

ABBV-333
—Not reported
Sunakiment
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

ABBV-333: no structured comparison results are available for Asthma.

Sunakiment: no structured comparison results are available for Asthma.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ABBV-333's landscape · Sunakiment's landscape